Skin Cancer & Surgery

Late-Stage Melanoma Hits Black Patients at 3x the Rate of White Patients

<![CDATA[Q&A: Strategies for Protecting Skin in Winter, With Jeanine B. Downie, MD]]>
jarmoluk / pixabay

Black patients are more than three times as likely as non-Hispanic white patients to be diagnosed with late-stage melanoma, and their estimated five-year melanoma survival rate sits at 70 percent versus 94 percent for white patients. Those figures anchor Jeanine B. Downie, MD's central argument in a new Dermatology Times Q&A: the biggest failures in skin cancer detection are not technological, they're behavioral and structural.

Where routine visits miss cancer

Downie's first target is the assumption that skin cancer looks like a dark, hurting, bleeding mole. It often doesn't. "Skin cancer does not always present as a traditional dark mole," she said, and it can develop anywhere on the body, including areas patients never examine. Any spot that is new, changing, or unusual warrants evaluation.

Her numbers are blunt: 99 percent of skin cancers are easily curable when caught early. Her prescription for clinicians is equally concrete:

  • Ask about new or changing spots at every routine visit, whatever the specialty.
  • Tell patients to photograph suspicious lesions and track changes over time.
  • Follow the Skin Cancer Foundation recommendation of an annual full-body professional skin examination for adults.
  • Tell patients not to wait for the annual appointment if something looks wrong between visits.

What actually changes patient behavior?

Counseling fails when it turns into a lecture. Downie, who has practiced for 30 years, recommends anchoring sun protection to habits patients already have. "For the last 30 years, I have recommended that my patients put sunscreen next to their toothbrush or deodorant," she said. It works because it removes the memory burden. Phone-based monthly reminders for self-examinations do the same job.

The Skin Cancer Foundation backs clinicians with medically reviewed prevention brochures, monthly self-exam instructions, and its Seal of Recommendation, which flags products meeting standards set by the Foundation's Photobiology Committee.

Which patients get overlooked?

The misconception that darker skin doesn't develop skin cancer persists, and the data show the cost. Skin cancer accounts for 1 to 2 percent of all cancers in Black people, roughly 2 to 4 percent in Asian people, and 4 to 5 percent in Hispanic people. When it does occur in darker skin, diagnosis tends to come later, when treatment is harder.

The stage-at-diagnosis gap is stark: 52 percent of non-Hispanic Black patients and 26 percent of Hispanic patients receive an initial diagnosis of advanced-stage melanoma, versus 16 percent of non-Hispanic white patients.

Anatomic patterns matter too. Melanoma in Black patients frequently appears on the palms, the soles, and under or around the nails, areas with little sun exposure that get skipped in both self-exams and clinical checks. Downie wants comprehensive examinations regardless of skin tone, plus explicit conversations about personal and family history, prior sunburns, tanning bed use, and cumulative UV exposure.

Other high-attention groups: older adults with accumulated sun exposure, organ transplant recipients, and outdoor workers. WHO and International Labour Organization research found outdoor UV exposure raises nonmelanoma skin cancer risk by 60 percent, and an American Academy of Dermatology survey found about 50 percent of U.S. outdoor workers reported sunburn, a proven driver of melanoma incidence.

Bemotrizinol and AI: what to watch

Two developments top Downie's watch list. In June 2026, the FDA approved bemotrizinol (BEMT), the first new sunscreen active ingredient cleared for U.S. use in more than 25 years. More ingredient options could expand formulation choices and, potentially, consistency of use. The basics don't move: broad-spectrum protection, reapplied every two hours or after swimming or sweating.

On AI-assisted lesion detection, she is firmly cautious. Current tools can misdiagnose skin cancers, and she tells patients directly that AI is not a substitute for a dermatologist's training and judgment. Clinicians should know the capabilities and the limits while reinforcing professional exams and monthly self-checks.

What does this change for practice? Downie's math makes the case: skin cancer is 90 percent preventable with a solid UV-protection strategy and 99 percent treatable when caught early. Every workflow change that pushes those two numbers, from toothbrush-adjacent sunscreen to palm-and-sole exams, is where the gains are.

Source: dermatologytimes.com

Share this article:

Sophie Lindqvist

Show full bio

Market editor covering people, launches and day-to-day practice in Clinical dermatology, inflammatory skin disease and biologics at Derm Field.

More from Sophie Lindqvist →

Related articles

« Previous articleNext article »